Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

60 Degrees Pharmaceuticals (SXTP) Net Margin (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Net Margin for 4 consecutive years, with 529.43% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin rose 114986.0% to 529.43% in Q3 2025 year-over-year; TTM through Sep 2025 was 872.69%, a 82131.0% increase, with the full-year FY2024 number at 1387.57%, up 16014.0% from a year prior.
  • Net Margin was 529.43% for Q3 2025 at 60 Degrees Pharmaceuticals, up from 1718.63% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 7992.11% in Q3 2023 to a low of 15148.79% in Q1 2023.
  • A 4-year average of 1484.39% and a median of 1225.67% in 2025 define the central range for Net Margin.
  • Biggest YoY gain for Net Margin was 1544091bps in 2024; the steepest drop was -967139bps in 2024.
  • 60 Degrees Pharmaceuticals' Net Margin stood at 4457.05% in 2022, then crashed by -137bps to 1652.82% in 2023, then skyrocketed by 45bps to 902.08% in 2024, then soared by 41bps to 529.43% in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Net Margin are 529.43% (Q3 2025), 1718.63% (Q2 2025), and 1225.67% (Q1 2025).